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COVID-19 is a disease characterized by a strong inflammatory response in severe
cases, which fails to respond to corticosteroid therapy. In the context of the current
COVID-19 outbreak and the critical information gaps regarding the disease, several
different therapeutic strategies are under investigation, including the use of stem cells. In
the present manuscript, we provide an analysis of the rationale underlying the application
of stem cells to manage COVID-19, and also a comprehensive compendium of the
69 clinical trials underway worldwide aiming to investigate the application of stem cells
to treat COVID-19. Even though data are still scarce, it is already possible to observe
the protagonism of China in testing mesenchymal stem cells (MSCs) for COVID-19.
Furthermore, it is possible to determine that current efforts focus on the use of multiple
infusions of high numbers of stem cells and derived products, as well as to acknowledge
the positive results obtained by independent groups who publicized the therapeutic
benefits provided by such therapies in 51 COVID-19 patients. In such a rapid-paced
field, up-to-date systematic studies and meta-analysis will aid the scientific community to
separate hype from hope and offer an unbiased position to the society and governments.
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INTRODUCTION
In December 2019, the world witnessed the first reports of patients presenting pneumonia in the
city of Wuhan, China (1). Soon after, genome sequencing studies demonstrated that such cases
were associated with a new coronavirus, named Severe Acute Respiratory Syndrome CoronaVirus
2 (SARS-CoV-2). The disease caused by such a virus was named coronavirus disease 2019, or simply
COVID-19 (2).
The COVID-19 pandemic has taken aback governments, health systems, and also scientists. Still,
the formidable challenges of understanding the biology of SARS-CoV-2 and the pathophysiology of
COVID-19, in order to develop effective treatment and immunization protocols, have led to a fast
worldwide mobilization of the scientific community. Countless studies and position articles have
been published regarding COVID-19 and are set to expand rapidly.
Stem cells constitute important assets for animal-free experiments, providing cheaper,
and ethical alternatives to animal studies. In this sense, scientific papers have already
described the application of stem cells to generate new data regarding several aspects of
Saldanha-Araujo et al. MSCs for COVID-19 Treatment
SARS-CoV-2 (3), similar to what has been done with other
viral diseases in the past (4). In addition to the possible
application of stem cells in basic research, such cells are
also appealing tools for immunomodulation, as shown by
our group and others (5–12), as well as tissue regeneration,
with a great deal of accumulated knowledge regarding the
underlying mechanisms of action and decades of clinical
experience, as shown by our group and others (13–18). It
is well-established that Mesenchymal stem cells (MSCs) are
able to control the functions of most if not all immune cells,
and that such effects occur through a network of mechanisms
including direct cell-cell contact, and secretion of soluble
factors with immunosuppressive function (19, 20). MSCs may
therefore be promising tools for the management of disorders
involving immune system dysregulation, which may be the case
of COVID-19.
In the context of the world-wide COVID-19 pandemic,
clinical trials have been initiated, even though much necessary
information regarding the disease is still lacking. Over 1,700
clinical studies have been registered worldwide, focusing
on investigating COVID-19 and trying to validate novel
therapeutic regimens, immunization protocols, and anti-viral
strategies (World Health Organization International Clinical
Trials Registry Platform). Among them, 69 involve the use of
stem cells and stem cell-derived products.
In the present manuscript, we provide an up-to-date analysis
of the rationale and current studies involving the clinical
application of stem cells to manage COVID-19. Even though data
are still scarce, it is already possible to determine the state of the
art, the main groups dedicating efforts in the theme, and also
the short-term perspectives for COVID-19 management using
stem cells.
COVID-19 PATHOPHYSIOLOGY AND THE
RATIONALE FOR USING STEM CELLS
Coronaviruses were first isolated from patients with common
cold by Tyrrell and Bynoe in (21). They constitute enveloped,
positive-sense RNA viruses, capable of infecting various
mammals, including humans (21). The SARS-CoV-2 belongs
to the Nidovirales order, Coronaviridae family, Coronavirinae
subfamily. The Coronavirinae is further divided into the alpha,
beta, gamma, and delta coronaviruses.While coronaviruses alpha
and beta seem to have originated from mammals (especially
bats), the gamma and delta coronaviruses seem to derive
from pigs and birds (22). Prior to the present SARS-CoV-2
outbreak, coronaviruses were only thought to cause mild
infections in humans. Now it is considered that among the
seven coronaviruses subtypes that are capable of infecting
humans, the beta coronaviruses–including SARS-CoV-2 -, may
cause severe and fatal diseases. SARS-CoV-2 spreads mainly
through the respiratory airways through droplets that are shed
from the respiratory secretions of infected persons, but also
by direct personal contact (23). Recently, the SARS-Cov-2 has
been isolated from fecal samples of severe pneumonia patients,
suggesting other transmission routes (24).
It has been shown that SARS-Cov-2 is capable of infecting
angiotensin I converting enzyme 2 (ACE-2) receptor-positive
cells. Such a receptor is expressed by a wide variety of cell
types, including the lung epithelial and capillary endothelial
cells, in which it successfully replicates. Inflammatory cells were
shown to be potentially infected by SARS-CoV viruses, but only
leading to abortive infection (25). Still, viral entry engenders
both innate and adaptive immune response, which initiate in
loco, but soon are detectable in the serum of COVID-19 patients
(26). The local tissue alterations provoked by the virus infection
are characterized by intense inflammation, inflammatory cell
migration, and edema (Figure 1). The subsequent tissue
destruction and dysfunction are proportional to viral load
and ACE-2 expression, which is increased in patients under
Angiotensin-converting enzyme inhibitors /angiotensin receptor
blockers therapy (27–29). Local tissue damage engendered by the
viral infection is detectable by radiological analysis, even before
the patient presents pneumonia symptoms.
COVID-19 can also affect the heart, liver, kidneys and
alter the immune system (30), presenting a wide range of
clinical outcomes that range from mild to common, severe, and
critically severe states (26). In the latter scenario, patients require
advanced life support, which is of great concern to public health
systems (31).
The inflammatory response caused by SARS-Cov-2 is both
the primary mechanism of viral elimination, but also tissue
destruction and dysfunction (Figure 1). The internalization of
the virus in tissue and immune cells leads to activation of nuclear
factor-kappa B (NF-kB) pathway and secretion of a myriad of
inflammatory factors, including IL-1, IL-17, TNF-α, and INF-γ
(32–34). Hyperinflammation and cytokine storm, both of which
can promote multiple organ failure, have been observed in severe
and critically severe patients (35) justifying current efforts to
test the therapeutic benefit of anti-inflammatory interventions,
including corticosteroids, immunosuppressors, and inhibitors of
Janus kinase (36).
Mesenchymal Stem Cells (MSCs) can be obtained from
different tissues and are characterized by regenerative and
immunomodulatory properties, which render them exciting tools
for cell therapy. As reviewed by our group and others (10, 37,
38), MSCs present remarkable angiogenic, healing, antiapoptotic,
and immunomodulatory potential. Furthermore, due to the low
expression of MHC-I, MHC-II, and costimulatory molecules,
they can be generally recognized as immune evasive and safe
when used in allogeneic settings (39).
The immunomodulatory mechanisms of MSCs include cell
contact-dependent (40) and paracrine processes, including
the secretion of TNF-Stimulated Gene-6 (41), IL-10 (42),
indoleamine 2,3-dioxygenase (43), adenosine (9), and also
extracellular vesicles (7). Such processes lead to lower immune
cell maturation and activation, in addition to promoting the
differentiation of T-cells into regulatory T-cells (Tregs) (38).
Over 1,000 clinical studies have been performed up to date
investigating the therapeutic potential of MSCs for various
purposes, including diseases in which the immune system
response is exacerbated, such as rheumatoid arthritis (44),
Crohn’s disease (45), Systemic lupus erythematosus (46–49) and
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FIGURE 1 | Putative mechanisms of action of MSCs against lung inflammation caused by COVID-19. During SARS-CoV-2 infection, lung ACE-2 positive cells, such
as epithelial and capillary endothelial cells are infected, leading to cell damage, inflammatory signaling, and the release of cytokines and chemokines. The inflammatory
milieu promotes the activation of local macrophages, dendritic, and endothelial cells, which further secrete soluble factors and promote the migration of circulating
monocytes, granulocytes, as well as lymphocytes. This leads to a feed-forward process, characterized by inflammation, tissue destruction, and organ dysfunction.
MSCs and their secretome can be used to counteract inflammation through contact-dependent and also paracrine processes. MSCs, Mesenchymal Stem Cells;
Tregs, Regulatory T-cells. Created with BioRender.com.
graft- vs. -host disease (50). Despite the fact that many of such
trials are still in progress, the available data obtained during
the last 30 years clearly show that MSCs constitute promising
tools in the treatment of inflammatory diseases. Considering
inflammatory diseases, most consistent data relate to the use of
MSCs in the treatment of the graft-vs. -host disease, highlighting
the potential of MSCs to improve clinical signs of inflammation
and favoring patient survival (50–53). Similar observations have
been made in the context of other inflammatory disorders. For
instance, it has been reported that MSCs infusions promote
a reduction of the inflammatory status and ameliorates the
clinical signs of patients with rheumatoid arthritis (54, 55). In
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Crohn’s disease patients, several published studies revealed that
MSCs induce perianal fistula healing (56–59). In recognition
of the cited and other studies, FDA and EMA have conceded
commercial approval for some MSC-based products targeting
specific indications (e.g., Alofisel and Remestemcel-L, which are
indicated to treat anal fistulas in Crohn’s disease and graft- vs.
-host disease, respectively).
Frequently, the treatment with MSCs follows intravenous
administration of the cells. Interestingly, it has been shown
that in this scenario a significant percentage of MSCs are
rapidly trapped in the lungs upon intravenous injection, and
also that lesioned sites increase MSC migration and retention
(60). In the lung capillaries, the same occurs: upon injury, the
local production of the pro-inflammatory mediator Angiotensin
II (Ang II) is increased, and drives MSC migration in vivo
through interactions with the Angiotensin II type 2 receptor
(61–63). When trapped in the lungs, MSCs show the same
immunomodulatory behavior as described in other body sites,
such as the capacity of releasing anti-inflammatory cytokines
(64), and antimicrobial peptides (65) (Figure 1).
As revised by Khoury et al. (66), at least 6 preclinical studies
have been executed in order to investigate the therapeutic effects
of MSCs in rodent (5 studies) and porcine (1 study) models
of influenza virus infection. Two out of six studies described a
lack of efficacy of MSC treatment in such models, but the most
recent investigations (4 out of 6) have revealed positive outcomes,
such as survival rate and decreased virus-induced inflammation.
The capacity of influenza viruses to infect MSCs (which has
not been assessed in vivo), host age, the varied MSC sources
(umbilical cord and bone marrow), the different cell doses
and administration routes involved in the studies may all help
explaining the dissonant observations among research groups.
Clinically, the anti-inflammatory effects of MSCs have also
been investigated in the context of Acute Respiratory Distress
Syndrome (ARDS) with different etiologies (67–69). In a more
recent study, perhaps as a hint for the application of MSCs
for COVID-19 management, Chen et al. have infused MSCs
into influenza A (H7N9) patients and obtained a significant
reduction in mortality, compared to control group (70). In
the cited study, 17 patients with ARDS caused by H7N9
infection were treated with menstrual blood-derived MSCs.
While the control group (treated with antiviral agents, oxygen
inhalation, etc) presented 54.5% mortality, only 17.6% of
MSC-treated patients expired. Interestingly, 4 patients were
followed during 5 years, with no harmful effects during
this period.
Overall, the achieved results of MSC therapy for ARDS are
promising, but important information is lacking in the literature,
such as details on the management of control subjects, the time
between MSC infusions, details regarding registered deaths, as
well as other outcomes of interest, such as ventilator-free days
and ICU stay.
Therefore, considering the acquired experience of the
scientific and medical communities regarding the clinical
application of MSCs to modulate the immune response, as well as
the limited–but existent–pieces of evidence regarding the safety
and efficacy ofMSC therapy for viral respiratory infections,MSCs
have entered clinical investigation for COVID-19 treatment. The
current state of the art is reviewed below.
CURRENT EFFORTS TO TREAT COVID-19
BASED ON STEM CELL PRODUCTS
Using the terms “COVID-19” and “stem cells” we found
studies in the ClinicalTrials.gov database (June, 2020). We
complemented our search by assessing the complete list of
COVID-19 clinical trials registered in the World Health
Organization International Clinical Trials Registry Platform,
and searching for studies which included the term “stem
cells.” We finalized our search by accessing the European
Union Clinical Trials Register (https://www.clinicaltrialsregister.
eu). Studies that were withdrawn will not be mentioned in
the present manuscript. Two observational studies were also
removed from the list. We ended up with 69 clinical studies,
60 of which aim to investigate the therapeutic efficacy of MSCs
to treat COVID-19. One trial aims to investigate the use of
mononuclear cells, one trial investigates PRP in addition to
stem cells, and six trials focus on the use of MSC-derived
exosomes/conditioned media. One study aims to investigate the
therapeutic benefits promoted by the combination of MSCs with
ruxolitinib (Supplementary Table 1). One trial proposes the use
of human Embryonic Stem Cells to produce “Immunity- and
matrix-regulatory cells (NCT04331613). One trial focuses on
using MSCs as “educators” of patients’ mononuclear cells. By
educated cells, researchers refer to mononuclear cells briefly
co-cultured with MSCs ex vivo. As revised by Zhao (71),
such a co-culture procedure leads to decreased expression of
costimulatory molecules by T cells, increased Treg generation,
and TGF-b1 synthesis. Educated cells have shown to be safe in
clinical studies and to impose effective anti-inflammatory effects.
The strategies under investigation based on Mesenchymal Stem
Cells are illustrated in Figure 2, and involve different routes of
administration, as well as the use of both MSCs, as well as their
products, such as exosomes.
As expected, China hosts almost 50% of the detected trials (32
out of 69), but countries like the United States, Spain, France,
Jordan, Turkey, Egypt, and Brazil are also executing clinical trials
in the theme, underscoring the capacity of local scientists from
different parts of the globe to respond to the present scenario.
Furthermore, such data also reveals the capacity of each country
to enable scientists and companies to rapidly initiate complex
clinical studies, involving advanced therapy products. In Brazil,
for instance, the regulatory framework is very recent (latest
document being released by ANVISA in January 2020), even
though the country has already important experience in the field
of clinical application of stem cells (Brazilian institutions have
already registered 98 clinical trials involving the use of stem
cells, according to ClinicalTrials.gov. The first trial was registered
in 2005).
Cell dose and proposed regimens varied among studies, but,
importantly, we note that we could not find the number of
injected cells in some studies. Considering the information we
could gather from the aforementioned sources, the number of
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FIGURE 2 | MSC-based strategies to treat COVID-19 under investigation in current clinical trials. Most clinical trials are based on the intravenous injection of allogeneic
MSCs to treat COVID-19 patients. Other strategies include the isolation of MSC-derived exosomes, applied through inhalation, and also the temporary co-culture of
autologous polymorphonuclear cells (PBMCs) collected from COVID-19 patients with allogeneic MSCs, followed by the injection of the so-called “educated”
autologous PBMCs back to the COVID-19 patient. MSCs, Mesenchymal Stem Cells; PBMCs, Peripheral Blood Mononuclear Cells. Created with BioRender.com.
infused MSCs ranged between 0.5 × 106 and 1 × 107 cells/kg.
Few studies proposed single doses of 3 × 107, 4 × 107, and 2 ×
108 cells, regardless of the weight of the patient. Most frequently,
the mentioned doses will be injected three or even four times,
during short time intervals of 2 or 3 days. All studies will perform
intravenous cell infusion of cells. Two studies focusing on the
use of MSC-derived exosomes have opted for inhalation routes,
while the others propose intravenous infusion. Taken together,
the studies are using relatively high numbers of cells in very short
periods between doses, compared to most MSC clinical trials
performed so far (72). High MSC doses are only assessed in a
short time frame if derived from allogeneic MSC banks, which is
the case in the cited studies regarding COVID-19.
The source of the MSCs used in the trials is also a point
of variability in the detected studies. The most common source
observed was the umbilical cord/wharton’s jelly (proposed in 28
studies), followed by adipose tissue (9 out of 69), bone marrow
(9 out of 69), dental pulp (3 out 69), embryonic stem cells (2
out of 69) and olfactory mucosa, placenta, and menstrual blood
(1 study each). In 11 studies, the MSC source was unclear.
Finally, 2 studies used cardiosphere stem cells, and the others
did not involve stem cells directly (educated cells, conditioned
media, etc).
Currently, it has not been established that any specific
adult mesenchymal stem cell source is clearly superior to
others (38). Nevertheless, a recent meta-analysis study by
McIntyre et al. suggested that bone marrow- and cord blood-
derived MSCs promoted slightly better therapeutic results than
adipose tissue-derived MSCs in preclinical studies of acute
lung injury (73). They also point to superior results following
intratracheal administration of MSCs, compared to intravenous
and intraperitoneal routes. Even though COVID-19 is mainly
acknowledged as a respiratory syndrome, its systemic effects
beyond the respiratory tract have also come to light (30, 74,
75). Such notion differs from the preclinical studies focused on
lung injuries only, and justifies the choice of systemic routes of
administration of MSCs in the COVID-19 studies.
The McIntyre et al. meta-analysis (73) also presented data
which suggest that allogeneic MSCs led to better results than
xenogeneic, syngeneic and autologous counterparts. Another
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interesting feature of the executed analysis is the suggestion that
the use of frozen MSCs also led to superior results compared to
fresh cells. It is important to emphasize that the meta-analysis
executed by McIntyre et al. is based on relatively small number of
studies, preventing major conclusions. Nevertheless, considering
the logistics of obtaining high numbers of MSCs for therapy,
evidence incentivizing the use of allogeneic, frozen cells, are of
great value to support the design of clinical studies based on the
use of allogeneic MSC cryobanks.
Most studies are investing in randomized trials (47 out of
69 studies), but 21 out of 69 trials have control groups that
do not receive placebo (only local routine treatment), and 19
out of 69 studies lack control groups altogether. Only 29 out
of 69 studies include placebo groups. Understandably, placebo-
controlled clinical studies are controversial, especially when
withholding treatment poses a significant risk for patients (76).
Still, considering that most studies underway focus on the
investigation of MSCs as add-on therapies, this means that most
placebo groups would receive routine treatment, undermining
ethical considerations.
Previous experience has taught valuable lessons regarding
the importance of randomized studies, including control
groups (77). Therefore, the percentage of the gold standard,
randomized and double-blind clinical trials can be considered
below expectations.
In the last 20 years of clinical experience with MSCs, it is
beyond dispute that MSC therapy is safe (78, 79). As published
by Thomson et al. (80), data derived from 55 clinical studies
involving almost 3,000 patients who received MSC therapy
indicate that the procedure is safe in the short-, medium- and
long-term. Nevertheless, it is frequently difficult to correlate
cellular therapies with long-term adverse effects.
Since the COVID-19 pandemic is recent, it does not come as a
surprise that clinical evidence supporting the use ofMSCs to treat
the disease are still scarce. So far, few clinical studies have been
published describing the results ofMSC treatment for COVID-19
(Supplementary Table 2).
The study by Leng et al. (26) presented partial results
of clinical trial ChiCTR2000029990, registered in the Chinese
Clinical Trial Registry System (http://www.chictr.org.cn/index.
aspx). The publication describes the 14-day outcome of 10
COVID-19 patients. Considering the 3 patients with severe
COVID-19 who received placebo infusions, unfortunately, one
died, one presented acute respiratory distress syndrome, and
one presented severe COVID-19. Regarding the 7 patients
who received MSC treatment, therapeutic benefits were mainly
observed in the four patients with severe disease, and also in
the single patient with critically severe disease, in contrast to the
2 MSC-treated COVID-19 patients who were not classified as
severe. All MSC-treated patients survived and presented positive
outcomes, 3 of themwere discharged, and the authors mentioned
no adverse effects.
More recently, in a company announcement, Mesoblast
described no adverse effects and positive clinical data obtained
in march-april 2020 regarding 12 ventilator-dependent COVID-
19 patients who received two MSC infusions 4 days apart
from each other (81). Among treated subjects, 10 (83%)
survived and 9 (75%) came off ventilator during the period
of observation. In the document, the company mentions
two studies which describe contemporaneous data of 12%
survival among ventilator-dependent COVID-19. Since the
clinical study is still ongoing, it will be important to see the
final results of the study, which includes a placebo control
group and will, therefore, be able to provide more reliable
control data.
Also during April 2020, the compassionate use of
cardiosphere-derived cells (CDCs) was investigated by the
teams of Cedars-Sinai Medical Center and Capricor Inc
(82). According to the authors of the study, CDCs are much
different from the controversial cardiac progenitor cells, and
have already been investigated in more than 200 patients,
presenting anti-inflammatory and immunomodulatory capacity.
In the manuscript, the authors present the data regarding
6 ventilator-dependent COVID-19 patients, of which 100%
(6 out of 6) survived, and 66.6% (4 out of 6) weaned from
respiratory support and were discharged. Ferritin, lymphocyte
counts tended toward normalization in most patients. A control
group (n = 34) of critical COVID-19 patients with similar
baseline characteristics, and simultaneously hospitalized at the
same study site, was retrospectively analyzed and presented
18% mortality.
Two studies described data regarding individual COVID-19
patients who received umbilical cord-derived MSCs in different
regimens. Zhang et al. performed the infusion of a single dose
of 1 million cells/kg in a severe COVID-19 patient (83), who
significantly benefited from the therapy and was discharged 7
days following the procedure. Liang et al. (84) treated a critically
ill COVID-19 who failed to respond to previous glucocorticoid,
antiviral (lopinavir/ritonavir, IFN-α inhalation and oseltamivir)
and antibiotics (moxifloxacin, Xuebijing, methylprednisolone,
and immunoglobulin), with three doses of 50 million MSCs.
No adverse effects were observed, and the patient presented
clinical and biomarker improvements after the second cellular
infusion. Two days following the third cellular infusion, the
patient left ICU.
In recognition of the value of the paracrine signaling on
stem cell mechanism of action, stem cell derived exosomes were
also investigated for COVID-19 management. In the study by
Sengupta et al. (85), 24 COVID-19 patients received a single
dose of ExoFlo. Patients were separated in cohorts according to
clinical parameters. One patient presented dyspnea, 20 patients
presented hypoxemia and required non-invasive oxygen support,
and 3 patients presented respiratory failure and depended on
mechanical ventilation. All patients received standard treatment
of the institution at the time, composed of hydroxychloroquine
and azhytrominin. Exosome-treated patients also received
ExoFlo, which is a product of Direct Biologics, composed of
exosomes derived from bone marrow MSCs and containing
immunomodulatory molecules, growth factors and chemokines
(https://directbiologics.com/growth-factors/). The amount of
exosomes contained in the applied dose is unclear, but no adverse
effects were registered related to the exosome treatment and
clinical benefits were observed. Of the 24 patients which received
ExoFlo, only 4 expired and 3 remained critically ill. Seventeen
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recovered, and therapeutic benefits peaked after 3–4 days from
infusion, suggesting the possibility of performing more than
one infusion.
As discussed by Leng et al. (26), it is important to point
out that–different from lung alveolar and endothelial cells -
, bone-marrow cells lack ACE-2 receptors. Therefore, it is
possible that bone marrow derived-MSCs lack ACE-2 receptors,
but Leng et al. were the first to show experimental evidence
in this sense (i.e., RNASeq analysis), suggesting that the
infused cells would not further replicate SARS-CoV-2. At this
point, the expression of ACE-2 in stem cells of other sources
is unclear.
As discussed, the rationale for using MSCs to treat COVID-19
is to revert the complex cytokine storm elicited by the SARS-
CoV-2, similar to what has already been described for other
viruses (86). In the scenario in which a single limited intervention
may fail to revert the complex pathophysiology of COVID-19,
the MSCs constitute a highly appealing therapeutic strategy. As
aforementioned, MSCs cells act in several different processes of
innate and adaptive immunity, possibly leading to changes in
the overall activation of the immune system in patients with
inflammatory diseases. MSCs also seem to exert therapeutic
benefits by secreting anti-apoptotic and regenerative factors.
In the study of Leng et al. different from the placebo controls,
severe and critically severe COVID-19 patients who received
MSC infusion presented a significant increase in Tregs, and also
a decrease in overactivated T and NK cells. Soluble factor analysis
in the patients‘ serum revealed that treated patients presented
increased IL-10, IP-10, VEGF levels, and also lower TNF-
a production, compared to untreated patients. After running
RNASeq analysis in theMSCs used for therapy, the authors found
that such cells present high mRNA levels of important anti-
inflammatory and trophic factors. The other published studies
also pointed to improvements in biochemical parameters, as well
as cytokines. Most importantly, publications point to the safety
and efficacy of the procedures, which led to significant clinical
improvements in fever, pneumonia, diarrhea, oxygenation, etc,
ultimately leading to mechanical ventilation weaning, and even
hospital discharge.
CONCLUDING REMARKS
Taken together, the present data reveal that stem cells and
stem cell-derived strategies are currently under investigation
as therapeutic tools to manage COVID-19, and also that
the limited observations published so far point to the safety
and efficacy of such therapies in the short-term, at least
in severe and critically severe patients. The replication
of the positive outcomes by independent groups was an
important milestone recently achieved in the field. The
current data, albeit preliminary and descriptive in nature, are
promising. Nevertheless, the comparison between different
therapeutic regimens, including various doses, MSC sources,
and injection routes in the short-term, as well as in long-
term, will provide valuable information about how to
potentialize therapeutic outcomes. In the safety assessment
side, patients need to be followed for long periods after stem
cell therapy, since the angiogenic and immunomodulatory
effects of MSCs could influence other outcomes, such as cancer
progression (87).
Drawing anymajor conclusions regarding the use of stem cells
and stem cell-derived products at this point is impossible, due
to the small evidence accumulated so far. Moreover, the lack of
full detailed data of published studies may compromise future
analysis as well. In this sense, the fact that a few studies cited here
present incomplete data regarding patients, clinical outcomes,
and other parameters is an important limitation of our study.
Nevertheless, such a limitation has also been detected as an issue
in previous works in the theme (66, 88, 89).
Cell therapies are complex and present high costs; therefore,
it will be paramount to carefully analyze the effect of such a
therapeutic strategy according to sensitive parameters, such as
time in ICU, time to recovery and duration of hospitalization.
Still, advanced therapies are hardly seen as a unique alternative
to manage a pandemic, but rather as an alternative to possibly
save patients in severe or critically-severe conditions. Cell-
free strategies under investigation are more easily scaled-
up, and may simplify the logistics and regulatory path for
commercial registration.
Preliminary data regarding the safety and efficacy of MSC
therapy for COVID-19 is positive and has been obtained by
independent groups. A second generation of trials adhering
to rigorously designed blind, randomized, placebo-controlled
protocols must now be pursued, with the aid of experienced
clinical and basic science investigators.
The stem cell sector suffers from much hype and,
unfortunately, unproven stem cell therapies for COVID-19
(and other disorders) are being offered worldwide, as alerted
by the International Society for Cell & Gene Therapy (90), and
more thoroughly reviewed by Turner (91). In such a rapid-paced
field, systematic studies and meta-analysis will aid the scientific
community to separate hype from hope and offer an unbiased
position to the society.
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